Evidence map›Paper›PMID 40672959›Full record

ArticleFrontiers in immunology2025

The level of I-FABP and IgA/IgG to beta-lactoglobulin in mothers at risk for gestational diabetes and in their children: association with antibodies to

Tamara Vorobjova, Aili Tagoma, Celeste Peterson, Ija Talja, Anu Bärenson, Kristi Alnek, Helis Janson, Kaja Metsküla, Anne Kirss, Epp Sepp and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tamara VorobjovaDepartment of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Aili TagomaDepartment of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Celeste PetersonDepartment of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Ija TaljaDepartment of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Anu BärensonDepartment of Pediatrics, University of Tartu, Children's Clinic of Tartu University Hospital, Tartu, Estonia.
Kristi AlnekDepartment of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Helis JansonDepartment of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Kaja MetskülaDepartment of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Anne KirssWomen's Clinic, Tartu University Hospital, Tartu, Estonia.
Epp SeppDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Tiiu RööpDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Siiri KõljalgDepartment of Microbiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Raivo UiboDepartment of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The mechanisms underlying gestational diabetes mellitus (GDM) and their impact on maternal and child immunity remain unclear. We hypothesize that gut microbiome alterations and increased small intestinal permeability contribute to GDM. Intestinal fatty acid-binding protein (I-FABP) leakage and elevated IgA/IgG against beta-lactoglobulin may indicate mucosal damage and may serve as biomarkers. Methods: This study evaluated I-FABP and IgA/IgG levels against beta-lactoglobulin in mothers with and without GDM (n=100) and in their children (n=87 at time point 1 (TP1), n=79 at time point 2 (TP2). Levels of antibody to Results: I-FABP and IgA/IgG levels did not significantly differ between mothers with and without GDM. However, children at TP1 had significantly higher I-FABP, IgA and IgG levels to beta-lactoglobulin than their mothers (p<0.01). In children, both I-FABP and IgA levels to beta-lactoglobulin declined with age (p<0.05). The children of mothers with GDM had higher IgA levels to beta-lactoglobulin (p=0.004). I-FABP was inversely correlated with IgA to Conclusion: Higher I-FABP and IgA levels to beta-lactoglobulin in children suggest increased intestinal permeability compared to adults. Only IgA to beta-lactoglobulin was significantly elevated in the children of mothers with GDM.

Indexed as

Antibodies, BacterialBifidobacterium breveDiabetes, GestationalFatty Acid-Binding ProteinsImmunoglobulin AImmunoglobulin GLactoglobulinsAdultBiomarkersChildChild, PreschoolFemaleGastrointestinal MicrobiomeHumansInfantMaleAntibodies, BacterialBiomarkersFatty Acid-Binding ProteinsImmunoglobulin AImmunoglobulin GLactoglobulinsELISAflow cytometrygestational diabetes mellitusI-FABPIgA and IgG to beta-lactoglobulinIgA and IgG to Bifidobacteriumimmunoblot

Identifiers

PMID40672959
PMCPMC12263606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.